Ami Fadia
Stock Analyst at Needham
(3.89)
# 494
Out of 4,479 analysts
237
Total ratings
49.05%
Success rate
8.96%
Average return
Main Sectors:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Buy | $130 | $110.36 | +17.80% | 19 | Jun 28, 2024 | |
| SAGE Sage Therapeutics | Reiterates: Hold | n/a | $10.82 | - | 12 | Jun 28, 2024 | |
| BIIB Biogen | Reiterates: Buy | $294 | $228.82 | +28.49% | 27 | Jun 28, 2024 | |
| COGT Cogent Biosciences | Reiterates: Buy | $18 | $8.24 | +118.45% | 15 | Jun 27, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Buy | $52 | $30.00 | +73.33% | 22 | Jun 25, 2024 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $145 | $39.27 | +269.24% | 1 | Jun 24, 2024 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Buy | $33 | $13.46 | +145.17% | 13 | Jun 19, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $90 → $94 | $68.54 | +37.15% | 20 | Jun 18, 2024 | |
| MRUS Merus | Maintains: Buy | $66 → $92 | $53.09 | +73.29% | 18 | May 28, 2024 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $22 | $13.89 | +58.39% | 24 | May 9, 2024 | |
| RVMD Revolution Medicines | Reiterates: Buy | $46 | $37.38 | +23.06% | 11 | May 9, 2024 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Buy | $30 | $15.84 | +89.39% | 4 | May 9, 2024 | |
| IMRX Immuneering | Reiterates: Buy | $15 | $1.09 | +1,276.15% | 7 | May 8, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $222 | $105.09 | +111.25% | 17 | May 2, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Hold | n/a | $137.49 | - | 3 | May 2, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $43 | $19.81 | +117.06% | 10 | Apr 10, 2024 | |
| AMRN Amarin Corporation | Maintains: Outperform | n/a | $0.71 | - | 1 | Feb 1, 2021 | |
| PCRX Pacira BioSciences | Downgrades: Market Perform | n/a | $22.74 | - | 3 | Jan 21, 2021 | |
| ITRM Iterum Therapeutics | Maintains: Market Perform | n/a | $1.09 | - | 3 | Oct 1, 2020 | |
| PRGO Perrigo Company | Maintains: Outperform | n/a | $25.99 | - | 3 | Sep 17, 2020 | |
| TEVA Teva Pharmaceutical | Upgrades: Market Perform | n/a | $16.55 | - | 2 | Oct 1, 2018 | |
| HRTX Heron Therapeutics | Initiates: Outperform | n/a | $2.74 | - | 1 | Jan 3, 2018 | |
| SCPH scPharmaceuticals | Initiates: Outperform | n/a | $4.21 | - | 1 | Dec 12, 2017 |
Blueprint Medicines
Jun 28, 2024
Reiterates: Buy
Price Target: $130
Current: $110.36
Upside: +17.80%
Sage Therapeutics
Jun 28, 2024
Reiterates: Hold
Price Target: n/a
Current: $10.82
Upside: -
Biogen
Jun 28, 2024
Reiterates: Buy
Price Target: $294
Current: $228.82
Upside: +28.49%
Cogent Biosciences
Jun 27, 2024
Reiterates: Buy
Price Target: $18
Current: $8.24
Upside: +118.45%
Harmony Biosciences Holdings
Jun 25, 2024
Reiterates: Buy
Price Target: $52
Current: $30.00
Upside: +73.33%
Praxis Precision Medicines
Jun 24, 2024
Initiates: Buy
Price Target: $145
Current: $39.27
Upside: +269.24%
Day One Biopharmaceuticals
Jun 19, 2024
Reiterates: Buy
Price Target: $33
Current: $13.46
Upside: +145.17%
Intra-Cellular Therapies
Jun 18, 2024
Maintains: Buy
Price Target: $90 → $94
Current: $68.54
Upside: +37.15%
Merus
May 28, 2024
Maintains: Buy
Price Target: $66 → $92
Current: $53.09
Upside: +73.29%
Avadel Pharmaceuticals
May 9, 2024
Reiterates: Buy
Price Target: $22
Current: $13.89
Upside: +58.39%
Revolution Medicines
May 9, 2024
Reiterates: Buy
Price Target: $46
Current: $37.38
Upside: +23.06%
ACADIA Pharmaceuticals
May 9, 2024
Reiterates: Buy
Price Target: $30
Current: $15.84
Upside: +89.39%
Immuneering
May 8, 2024
Reiterates: Buy
Price Target: $15
Current: $1.09
Upside: +1,276.15%
Jazz Pharmaceuticals
May 2, 2024
Reiterates: Buy
Price Target: $222
Current: $105.09
Upside: +111.25%
Neurocrine Biosciences
May 2, 2024
Reiterates: Hold
Price Target: n/a
Current: $137.49
Upside: -
Bicycle Therapeutics
Apr 10, 2024
Reiterates: Buy
Price Target: $43
Current: $19.81
Upside: +117.06%
Amarin Corporation
Feb 1, 2021
Maintains: Outperform
Price Target: n/a
Current: $0.71
Upside: -
Pacira BioSciences
Jan 21, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $22.74
Upside: -
Iterum Therapeutics
Oct 1, 2020
Maintains: Market Perform
Price Target: n/a
Current: $1.09
Upside: -
Perrigo Company
Sep 17, 2020
Maintains: Outperform
Price Target: n/a
Current: $25.99
Upside: -
Teva Pharmaceutical
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $16.55
Upside: -
Heron Therapeutics
Jan 3, 2018
Initiates: Outperform
Price Target: n/a
Current: $2.74
Upside: -
scPharmaceuticals
Dec 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $4.21
Upside: -